GEHC•GE HealthCare shares fell more than 1% to $63.55 after it agreed to buy privately held Sofie Biosciences for $945 million in cash. The deal would give GE HealthCare U.S. rights to the experimental PET imaging agent FAPI-74.
GE HealthCare said the acquisition would give it U.S. rights to FAPI-74, an experimental PET imaging agent in late-stage testing that could be used to detect several types of cancer; it already owns rights to the product outside the U.S. Sofie would continue manufacturing products for existing customers, including other radiopharma companies, after the transaction closes, which is expected in the first half of 2027.
